These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 35451929)

  • 1. 2-methoxyestradiol inhibits melanoma cell growth by activating adaptive immunity.
    Hua W; Huang X; Li J; Feng W; Sun Y; Guo C
    Immunopharmacol Immunotoxicol; 2022 Aug; 44(4):541-547. PubMed ID: 35451929
    [No Abstract]   [Full Text] [Related]  

  • 2. B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade.
    Singh S; Roszik J; Saini N; Singh VK; Bavisi K; Wang Z; Vien LT; Yang Z; Kundu S; Davis RE; Bover L; Diab A; Neelapu SS; Overwijk WW; Rai K; Singh M
    Front Immunol; 2022; 13():794684. PubMed ID: 35720386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.
    Pilon-Thomas S; Mackay A; Vohra N; Mulé JJ
    J Immunol; 2010 Apr; 184(7):3442-9. PubMed ID: 20194714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exercise sensitizes PD-1/PD-L1 immunotherapy as a hypoxia modulator in the tumor microenvironment of melanoma.
    Yan H; Jiang A; Huang Y; Zhang J; Yang W; Zhang W; Liu T
    Front Immunol; 2023; 14():1265914. PubMed ID: 37876940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maprotiline Prompts an Antitumour Effect by Inhibiting PD-L1 Expression in Mice with Melanoma.
    Liang L; Li Y; Jiao Y; Zhang C; Shao M; Jiang H; Wu Z; Chen H; Guo J; Jia H; Zhao T
    Curr Mol Pharmacol; 2024; 17(1):e18761429259562. PubMed ID: 37982288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Albendazole induces an anti-tumor effect and potentiates PD-L1 blockade immunotherapy.
    Zhang W; He Z; Liang F; Gong J; Tan L; Yang J; Song S; Xie L; Lu Y
    J Cancer Res Clin Oncol; 2023 Dec; 149(18):16763-16778. PubMed ID: 37730912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Immunomodulatory Gallotanin-Rich Fraction From
    Lasso P; Gomez-Cadena A; Urueña C; Donda A; Martinez-Usatorre A; Romero P; Barreto A; Fiorentino S
    Front Immunol; 2020; 11():584959. PubMed ID: 33312174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B16 melanoma control by anti-PD-L1 requires CD8+ T cells and NK cells: application of anti-PD-L1 Abs and Trp2 peptide vaccines.
    Ji S; Lee J; Lee ES; Kim DH; Sin JI
    Hum Vaccin Immunother; 2021 Jul; 17(7):1910-1922. PubMed ID: 33522416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
    Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
    Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model.
    Merino M; Lozano T; Casares N; Lana H; Troconiz IF; Ten Hagen TLM; Kochan G; Berraondo P; Zalba S; Garrido MJ
    J Nanobiotechnology; 2021 Apr; 19(1):102. PubMed ID: 33849551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of Photodynamic Therapy and a Flagellin-Adjuvanted Cancer Vaccine Potentiated the Anti-PD-1-Mediated Melanoma Suppression.
    Hwang HS; Cherukula K; Bang YJ; Vijayan V; Moon MJ; Thiruppathi J; Puth S; Jeong YY; Park IK; Lee SE; Rhee JH
    Cells; 2020 Nov; 9(11):. PubMed ID: 33171765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma.
    Chen X; Wang K; Jiang S; Sun H; Che X; Zhang M; He J; Wen Y; Liao M; Li X; Zhou X; Song J; Ren X; Yi W; Yang J; Chen X; Yin M; Cheng Y
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35347072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 16. Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro.
    Tay WT; Fang YH; Beh ST; Liu YW; Hsu LW; Yen CJ; Liu PY
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
    Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymer-lipid hybrid nanovesicle-enabled combination of immunogenic chemotherapy and RNAi-mediated PD-L1 knockdown elicits antitumor immunity against melanoma.
    Wang C; Shi X; Song H; Zhang C; Wang X; Huang P; Dong A; Zhang Y; Kong D; Wang W
    Biomaterials; 2021 Jan; 268():120579. PubMed ID: 33278683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-1 blockade combined with IL-33 enhances the antitumor immune response in a type-1 lymphocyte-mediated manner.
    He H; Shi L; Meng D; Zhou H; Ma J; Wu Y; Wu Y; Gu Y; Xie W; Zhang J; Zhu Y
    Cancer Treat Res Commun; 2021; 28():100379. PubMed ID: 33951555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cilengitide, an αvβ3-integrin inhibitor, enhances the efficacy of anti-programmed cell death-1 therapy in a murine melanoma model.
    Pan X; Yi M; Liu C; Jin Y; Liu B; Hu G; Yuan X
    Bioengineered; 2022 Feb; 13(2):4557-4572. PubMed ID: 35142593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.